PT  - JOURNAL ARTICLE
AU  - Levy, David T.
AU  - Liber, Alex
AU  - Cadham, Christopher J.
AU  - María Sánchez-Romero, Luz
AU  - Hyland, Andrew
AU  - Cummings, K. Michael
AU  - Douglas, Clifford E.
AU  - Meza, Rafael
AU  - Henriksen, Lisa
TI  - Follow the Money: A Closer Look at US Tobacco Industry Marketing Expenditures
AID  - 10.1101/2021.08.08.21261761
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.08.21261761
4099  - http://medrxiv.org/content/early/2021/08/09/2021.08.08.21261761.short
4100  - http://medrxiv.org/content/early/2021/08/09/2021.08.08.21261761.full
AB  - Introduction While much of the concern with tobacco industry marketing has focused on direct media advertising, a less explored form of marketing strategy is to discount prices. Price discounting is important because it keeps the purchase price low and can undermine the impact of tax increases.Methods We examine annual marketing expenditures from 1975 to 2019 by the largest cigarette and smokeless tobacco companies. We consider three categories: direct advertising, promotional allowances, and price discounting. In addition to considering trends in these expenditures, we examine how price discounting expenditures relate to changes in product prices and excise taxes.Results US direct advertising expenditures for cigarettes fell from 80% of total industry marketing expenditures in 1975 to less than 3% in 2019, while falling from 39% in 1985 to 6% in 2019 for smokeless tobacco. Price-discounting expenditures for cigarettes became prominent after the Master Settlement Agreement and related tax increases in 2002. By 2019, 87% of cigarette marketing expenditures were for price discounts and 7% for promotional allowances. Smokeless marketing expenditures were similar: 72% for price promotions and 13% for promotional allowances. Price discounting increased with prices and taxes until reaching their currently high levels.Conclusions While much attention focuses on direct advertising, other marketing practices, especially price discounting, has received less attention. Local, state and federal policies that use non-tax mechanisms to increase tobacco prices and restrict industry contracts with retailers are needed to offset/disrupt industry marketing expenditures. Further study is needed to better understand industry decisions about marketing expenditures.Key pointsWhile much of the concern with tobacco industry marketing has focused on direct media advertising, a less explored form of marketing strategy is to discount prices. Price discounting is important because it keeps the purchase price low and can undermine the impact of tax increases, contributing to tobacco initiation and exacerbating socio-economic health disparities.While cigarette and smokeless tobacco industry direct marketing expenditures have drastically fallen over time, price-discounting expenditures have dramatically increased in line with increases in prices and taxes.Local, state and federal policies that restrict non-tax mechanisms to increase tobacco prices and restrict industry contracts with retailers are needed to offset/disrupt industry marketing expenditures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded primarily through National Cancer Institute (NCI) and Food and Drug Administration (FDA) grant U54CA229974. Funding was also received through a grant from the National Cancer Institute (P01CA200512) and the National Cancer Institute (P01CA225597).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data is publicly available and does not require approvalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is publicly available.